The major anticancer/antimetastatic effect of MePip-SF5 may therefore be related rather to interference with the cell cycle of the rapidly proliferating melanoma cells because Bub-1, an important negative regulator of the cell cycle, was downregulated by MePip-SF5 treatment (Figure 4). The gene discussed is BUB1; the disease is melanoma.